LOQTORZI TORIPALIMAB-TPZI 特瑞普利单抗

Effects and efficacy: This product is used for melanoma. The PD-1 receptor expressed by T cells binds to its ligands PD-L1 and PD-L2, which can inhibit T cell proliferation and cytokine production. The PD-1 ligand of some tumor cells is upregulated, which can inhibit the immune surveillance of activated T cells on tumors. Teplizumab can bind to PD-1 on the surface of T cells, blocking its binding to the ligands PD-L1 and PD-L2, thereby eliminating the immunosuppression of tumor cells on the PD-1 signaling pathway. This product can promote T cell proliferation, activate T cell function, and inhibit tumor growth.
Usage and Dosage: The recommended dose of this product is 3 mg/kg, intravenous infusion once every 2 weeks until disease progression or intolerable toxicity occurs. Atypical reactions have been observed in patients receiving this product to treat tumors (for example, temporary enlargement of the tumor or the appearance of new small lesions in the first few months of treatment, followed by tumor shrinkage). The same drugs produced by different manufacturers may have inconsistent instructions. If you find that the instructions are inconsistent before taking the drug, please consult a doctor or pharmacist in time.
Contraindications:
Contraindicated if allergic to this product. Contraindicated during pregnancy. Contraindicated during lactation. Use with caution while driving.
Related dosage forms:
Injection
View more